<DOC>
	<DOCNO>NCT00448201</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , busulfan fludarabine , donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Immunosuppressive therapy may improve bone marrow function may effective treatment hematologic cancer disease . PURPOSE : This clinical trial study side effect well give busulfan fludarabine without antithymocyte globulin follow donor stem cell transplant work treat patient hematologic cancer disease .</brief_summary>
	<brief_title>Reduced-Intensity Busulfan Fludarabine With Without Antithymocyte Globulin Followed Donor Stem Cell Transplant Treating Patients With Hematologic Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical efficacy toxicity profile nonmyeloablative preparative regimen comprise busulfan fludarabine without anti-thymocyte globulin follow allogeneic hematopoietic stem cell transplantation patient hematologic cancer disease . - Determine feasibility regimen patient . - Establish treatment-related mortality first 6 month less 20 % patient treated regimen . Secondary - Determine response rate ( disease-specific partial response complete response ) patient treat regimen . - Determine overall progression-free survival patient treat regimen . - Determine percent donor chimerism immunologic recovery , include dendritic cell recovery , patient treat regimen . - Determine risk acute chronic graft-versus-host disease toxicity patient treat regimen . - Assess overall nonhematologic grade 3 4 toxicity regimen , include incidence veno-occlusive disease pulmonary toxicity , patient . OUTLINE : Patients assign 1 4 treatment group accord disease type donor type . - Preparative regimen : - Group 1 ( patient acute myeloid leukemia [ AML ] , acute lymphoblastic leukemia [ ALL ] , IPSS [ International Prognostic Scoring System score ] high-risk myelodysplastic syndrome [ HR MDS ] , chronic myelogenous leukemia [ CML ] HLA-matched related donor [ MRD ] ) : Patients receive fludarabine phosphate IV 30 minute day -7 -3 busulfan IV continuously 48 hour day -6 -5 . - Group 2 ( patient AML , ALL , IPSS HR MDS , CML HLA-matched unrelated donor [ MUD ] mismatch related donor [ MMRD ] ) : Patients receive fludarabine phosphate busulfan group 1 anti-thymocyte globulin IV 4 hour day -8 . - Group 3 ( patient diseases MRD ) : Patients receive fludarabine phosphate busulfan group 1 anti-thymocyte globulin group 2 . - Group 4 ( patient disease MUD MMRD ) : Patients receive fludarabine phosphate busulfan group 1 anti-thymocyte globulin IV 4 hour day -8 -7 . - Allogeneic stem cell transplantation : All patient undergo allogeneic peripheral blood stem cell transplantation day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously daily begin day 5 ( group 1 2 ) day 7 ( group 3 4 ) continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : All patient receive oral tacrolimus twice daily day -1 120 followed taper day 180 . Patients group 1 2 also receive methotrexate IV day 1 , 3 , 6 . - Donor lymphocyte infusion ( DLI ) : After day 120 , patient progressive disease stable disease immunosuppression evidence active GVHD may receive DLI . Treatment DLI may repeat every 8 week 3 total infusion absence disease response GVHD . Peripheral blood and/or bone marrow sample collect baseline 30 , 60 , 90 , 120 , 180 day post-transplantation . Chimerism ( include follow subset : whole blood , T-cells define CD3 positivity , B-cells define CD19 positivity , myeloid cell define CD14 CD15 positivity ) analyze polymerase chain reaction technology . After restaging Days 90 100 Days 150 180 , patient follow every 6 month 1 year yearly maximum 5 year study entry .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Chronic lymphocytic leukemia ( CLL ) , meet follow criterion : Absolute lymphocyte count &gt; 5,000/mm³ Lymphocytes must appear morphologically mature &lt; 55 % prolymphocytes Lymphocyte phenotype expression CD19 CD5 Prolymphocytic leukemia ( PLL ) , meet follow criterion : Absolute lymphocyte count &gt; 5,000/mm³ More 55 % prolymphocytes Morphologically diagnose Chronic myelogenous leukemia ( CML ) , meet follow criterion : Diagnosis CML similar myeloproliferative disorder base ( 9 ; 22 ) relate ( 9 ; 12 ) cytogenetic abnormality AND characterize elevated WBC count peripheral blood bone marrow In first chronic phase CML candidate treatment reduceddose busulfan Patients cytogenetic abnormality , ( 9 ; 12 ) , associate aggressive clinical course eligible NonHodgkin 's lymphoma ( NHL ) , meet follow criterion : Any WHO class histologic subtype allow Core biopsy acceptable provide contain adequate tissue primary diagnosis immunophenotyping Bone marrow biopsy sole mean diagnosis allow follicular lymphoma Hodgkin 's lymphoma , meet follow criterion : Any WHO class histologic subtype allow Core biopsy acceptable provide contain adequate tissue primary diagnosis immunophenotyping Multiple myeloma , meet follow criterion : Active disease require treatment ( DurieSalmon stag I , II , III ) Acute myeloid leukemia document control , define &lt; 10 % bone marrow blast circulate blast Acute lymphoblastic leukemia , meet follow criterion : In early first relapse beyond OR first complete remission 1 follow highrisk feature : ( 9 ; 22 ) ( 4 ; 11 ) WBC count &gt; 30,000/mm³ presentation NonTcell phenotype More 30 year age Agnogenic myeloid metaplasia/myelofibrosis Patients transfusion dependent evolve myelodysplastic leukemic feature highrisk cytogenetic abnormality eligible Myelodysplastic syndrome ( MDS ) define WHO criteria Meets 1 follow criterion : Over 55 year age Ineligible busulfanbased therapy base diminish organ function poor performance status Indolent chemotherapyresponsive CLL , lowgrade NHL , small lymphocytic lymphoma , PLL Patients undergone prior autologous stem cell transplantation preferentially enrol clinical trial CALGB100002 , available patient eligible HLAmatched mismatch related donor HLAmatched unrelated donor available HLAidentical sibling ( 6/6 9/10 ) ( minimal serologic typing required class I [ A , B ] ; molecular typing require class II [ DRB1 ] ) 9/10 match unrelated donor ( MUD ) ( molecular analysis HLA A , B , C , DRB1 , DQB1 high resolution typing require ) 5/6 MUD ( molecular analysis HLA A , B , DRB1 require ) No syngeneic donor PATIENT CHARACTERISTICS : Creatinine clearance ≥ 40 mL/min Bilirubin ≤ 3 time upper limit normal ( ULN ) AST ≤ 3 time ULN DLCO &gt; 40 % symptomatic pulmonary disease LVEF ≥ 30 % MUGA No uncontrolled diabetes mellitus active serious infection No known hypersensitivity Escherichia coliderived product No HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior chemotherapy , radiotherapy ( except prophylactic cranial xray therapy ) , surgery</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>